Following on from information provided to NICE by the company in April 2022, the appraisal of Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3999 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 May 2023 | Discontinued. Following on from information provided to NICE by the company in April 2022, the appraisal of Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual